Charles River Laboratories to acquire gene therapy CDMO Vigene Biosciences
Charles River Laboratories International has signed an all-cash deal worth $292.5 million to acquire Vigene Biosciences, a US-based gene therapy contract development and manufacturing organization (CDMO) that offers viral vector-based gene delivery solutions. Vigene Biosciences also stands to earn up to $57.5 million in contingent additional payments based on its future performance. The acquisition is […]